Product/Composition:- | Lidocaine Transdermal Patches |
---|---|
Strength:- | 5 %, 10% |
Form:- | Transdermal Patches |
Reference Brands:- | Lidoderm(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Lidocaine transdermal patches inhibit nerve signal transmission by blocking sodium channels, providing targeted local anesthesia. Benefits include sustained pain relief, reduced systemic side effects, and convenience for managing localized nerve pain and post-herpetic neuralgia. They offer effective, long-lasting, opioid-free pain management in outpatient settings.
Lidocaine transdermal patches are approved in the EU and US for localized pain, including post-herpetic neuralgia. In the EU, brands like Lidoderm are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on extensive clinical data, pharmacovigilance, and manufacturing standards. Both regions require detailed dossiers for approval and continuous safety monitoring. Due to their use in pain management, strict prescribing and usage guidelines are enforced. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access for lidocaine patches, ensuring adherence to European and US standards for safe, effective pain relief.